In August 2025, Sanofi acquired the rights to develop and commercialize Redemplo in Greater China from Visirna Therapeutics, a majority-owned subsidiary of Arrowhead Pharmaceuticals.

Myqorzo and Redemplo approved in China Approval of Myqorzo for obstructive hypertrophic cardiomyopathy and Redemplo for familial chylomicronemia syndromeUnderscores Sanofi's long-term commitment to ...

A new study published in the journal of Cardiovascular Revascularization Medicine revealed that in patients with complex left ...

South African livestock producers are reporting a concerning increase in sudden calf deaths linked to a condition known as ...

People with type 2 diabetes are more likely to develop heart failure, but the reasons are not fully explained by cholesterol, blood pressure and blocked arteries alone. A new study adds another piece ...

Diabetes doesn’t just coexist with heart disease - it actively reshapes the heart’s machinery and the way it makes energy.

As of Tuesday, January 13, Lexeo Therapeutics, Inc.’s LXEO share price has dipped by 5.36%, which has investors questioning ...

Dr. Agrawal warns that winter cold triggers physiological stress, clots, and respiratory issues. Prevention via vaccination, ...

Both turmeric and magnesium can offer health benefits, but which is better for inflammation, heart health, and relaxation?

Structural alignment in fibrous tissues like myocardium and tendons is a key biomarker of physiological integrity and ...

The health department records 288 cases from December 21 to Wednesday morning, December 31, up 5% from 274 during the same period in 2024 ...

Named 'SleepFM', the model was developed by researchers, including those from the US' Stanford University, and trained on ...